^
Association details:
| Biomarker: | Chr del(8p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | fludarabine IV (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Del8p and TNFRSF10B loss are associated with a poor prognosis and resistance to fludarabine in chronic lymphocytic leukemia
Published date:
10/06/2023
Excerpt:
Interestingly, del8p patients treated with fludarabine-based regimens had a shorter time to next treatment (40 vs. 63 months; p=.002) and a shorter OS (10y OS: 46 vs. 82%; p<.001), including those with mutated IGHV (42 vs. 107 months; p=.015).
DOI:
https://doi.org/10.1080/10428194.2023.2250219
